Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; cellulose acetate; polyethylene oxide; macrogol 3350; hypromellose; iron oxide red; sodium chloride; titanium dioxide; propylene glycol; hyprolose; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - indications: nifedipine is indicated for: 1. the treatment of mild to moderate hypertension. 2. the prophylaxis of chronic stable angina pectoris.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sucrose; water for injections; polysorbate 20 - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd) - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) - diabetic macular oedema (dme) - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - aflibercept, quantity: 40 mg/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sucrose; polysorbate 20; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate - eylea (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet amd); - visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo); - diabetic macular oedema (dme); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo); - visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - radium (223ra) dichloride, quantity: 6600 kbq - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium citrate dihydrate - xofigo is indicated for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - acarbose -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - acarbose -